Text Size

The Role of Routine Bacterial Culture Including Tuberculosis During Bronchoscopy: A Prospective Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01167647
First received: July 21, 2010
Last updated: March 5, 2013
Last verified: March 2012
History of Changes
  Purpose

Many centers routinely culture bronchoscopy samples for bacteria and mycobacteria even when infections including tuberculosis (TB) are not strongly suspected. However, the value of this practice has been poorly defined.


Condition
Tuberculosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Routine Bacterial Culture Including Tuberculosis During

Resource links provided by NLM:

MedlinePlus related topics: Tuberculosis
U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • number of positive tuberculosis culture [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: July 2010
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
bronchoscopy patients

Detailed Description:

Many centers routinely culture bronchoscopy samples for bacteria and mycobacteria even when infections including tuberculosis (TB) are not strongly suspected. However, the value of this practice has been poorly defined. Unnecessary bronchial cultures of bacteria may lead to over treatment in patients without clinical evidence of infections and may increase the drug resistant strains.

In areas with a high prevalence of TB, routine bronchial cultures may detect clinically unsuspected TB in an appreciable proportion of cases. However, in population with a low prevalence of TB, routine culture of bronchial aspirates may incur an unnecessary expanse and may lead to over diagnosis and over treatment of patients with non pathogenic atypical mycobacteria detected by acid-fast bacillus strains.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All patients who will undergo a bronchoscopy examination at pulmonary department in Meir Medical Center and will sign on informed consent.

Criteria

Inclusion Criteria:

  1. patients who will undergo a bronchoscopy examination at pulmonary department in Meir Medical Center
  2. patients who will sign on informed consent. -

Exclusion Criteria:

  • 1)age under 18 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01167647

Locations
Israel
Pulmonary department, Meir Medical Center
Kfar Saba, Israel, 49100
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: David Shitrit, MD Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01167647     History of Changes
Other Study ID Numbers: MMC10-087-10.CTIL
Study First Received: July 21, 2010
Last Updated: March 5, 2013
Health Authority: Israel:Clalit Health Services

Keywords provided by Meir Medical Center:
Tuberculosis, culture, bronchoscopy

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on June 18, 2013